Genesis Therapeutics started in now-a16z venture capitalist Vijay Pande’s lab at Stanford, where Genesis co-founder and CEO Evan Feinberg did his Ph.D. A16z led Genesis’ 2023 $200 million series B alongside ...
The genome-editing technology can be supercharged by artificial intelligence—and the results are already being felt.
In 2025, we will see AI and machine learning begin to amplify the impact of Crispr genome ...
Company’s first offering, Ataraxis Breast, clinically validated in landmark study to be 30% more accurate than the current standard of care for breast cancer
$4 million in seed ...
The treatment has the potential to cure diseases, but high costs and a difficult delivery process have held it back.
Roche Holding AG is willing to pay more than $1 billion to solve one ...
New strategic partnership leverages the power of the Dyno platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets
Dyno to receive US$50 million upfront cash ...
The technology’s promise can sound like science fiction—it might help us adapt to a radically different climate, or grow organs for people in need—but experts are also concerned about ...
Four years ago, Jennifer Doudna and Emmanuelle Charpentier shared the Nobel Prize in chemistry for the development of a method for genome editing called CRISPR-Cas9.
In her lecture, Doudna detailed “extraordinary and exciting opportunities” for the technology ...
How do we develop and integrate breakthrough health technology into our lives?
From robot helpers to smart prosthetics to "smart skin" to CRISPR gene editing, our ability to build a ...
Prof Jennifer Doudna, the ‘Godmother of Crispr’, says ‘figuring out how to edit the brain is probably coming in the next decade’.
Jennifer Doudna says she is an “unlikely success ...
Why Jennifer Doudna is one of Fast Company’s 10 most innovative people of the last 10 years
Doudna codeveloped the revolutionary gene-editing technology known as CRISPR-Cas9. Now it’s leading to ...
"Reengineering Life: The Next Frontiers in Science" is Fareed Zakaria GPS's special report on CNN profiling Nobel Laureate and Innovative Genomics Institute founder Jennifer Doudna and the development, rise, ...
If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems ...
Parag Mallick, founder and chief scientist of Nautilus Biotechnology, hopes his company’s solutions will unlock the secrets of proteins, the building blocks of biology. Being a magician as well, ...
Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.
To read of AI’s feats in ...
Late blight is an old foe of humans. This disease catalysed the devastating Irish potato famine that began in 1845.
It is caused by a fungus-like pathogen, which quickly kills ...
For stretched public health budgets, high-tech treatments are hard to afford but some pre-emptive measures can prove good value.
As hay fever season arrives, once again, for allergy and asthma ...
The most striking evidence that artificial intelligence can provide profound scientific breakthroughs came with the unveiling of a program called AlphaFold by Google DeepMind.
In 2016 researchers at the company ...
As OpenAI's CEO, Altman is widely considered to be the face of artificial intelligence, reprogramming the way we'll live and work for years to come. His relentless push into ...
Expanding medical therapies based on Crispr gene-editing globally is “unrealistic” and the sector needs heavy investment to make the technology, which could transform treatment of diseases, accessible to all, ...
Venture capitalists are financing drugmakers seeking to improve upon today’s blockbuster weight-loss medications or combat their side effects.
New obesity medications have helped millions of people lose weight but can ...
BioAge Labs has reeled in the biotech industry’s largest private financing round so far in 2024 as the California startup goes full throttle on the hottest areas in obesity ...
In his January 20, 2024 TEDxBerkeley Talk, Dr. Benjamin Oakes delves into the profound potential of CRISPR technology and its ability to transform healthcare.
Dr. Oakes is co-founder and ...
Joe Betts-LaCroix didn’t have time to wait for architects, construction workers or really any of the normal things that go into building a new office, let alone a new ...
Dr. Alex Colville joins forces with Laura Deming to lead investments in longevity science moonshots, after deploying $100M fund last year while at Stanford
age1, a venture capital firm catalyzing ...
Inceptive’s Jakob Uszkoreit, a pioneer of the technology behind ChatGPT, attracts Nvidia funding to design ‘biological software’.
A biotech start-up founded by a former Google artificial intelligence expert has raised ...
Jakob Uszkoreit, one of the people who laid the groundwork for generative platforms such as ChatGPT, has secured $100 million in a Series A raise for an AI biotech ...
Chronic diseases like cancer, heart disease and diabetes, first hit the average American in their 60s. Cancer is usually diagnosed at 66, the average age for a first heart attack in ...
Scientists obsessed with aging are sketching a road map of how our bodies change as we grow old in the hopes that it will lead to treatments that could ...
The Atlantic celebrates science, tech, and a culture of curiosity.
Join us to explore how innovation borrows from unexpected corners, featuring Airbnb’s Brian Chesky, Google DeepMind’s Pushmeet Kohli, Anthropic’s Dario ...
Scientists are engineering microbes to make healthier compounds. They hope they’ll help treat disease and save the planet.
Microbes have been on my mind this week. These tiny organisms are ...
Hype springs eternal in medicine, but lately the horizon of new possibility seems almost blindingly bright. “I’ve been running my research lab for almost 30 years,” says Jennifer Doudna, ...
CRISPR pioneer Jennifer Doudna's company Scribe Therapeutics inked a major deal with Prevail Therapeutics potentially worth $1.5 billion to create genetic medicines for neurological and neuromuscular diseases. Scribe CEO ...
Scribe Therapeutics found another partner, this time with Prevail Therapeutics, a subsidiary of Eli Lilly, in a $75 million upfront deal for neuromuscular and neurological diseases.
Unlike Scribe’s ex vivo ...
Collaboration combines Scribe Therapeutics’ novel CRISPR by Design™ approach with Prevail Therapeutics’ deep expertise in developing genetic medicines for neurological disorders towards specified genetic targets
Scribe to receive ...
The times are changing in biopharma.
With the top drugmakers no longer committing most of their resources to the pandemic, biopharma is returning to its roots. But it’s clear the ...
Deep in the bellies of cows are tiny microbes that ferment grass and hay, breaking it down into fatty acids that serve as bovine energy—and into planet-warming methane gas. ...
When a startup called Retro Biosciences eased out of stealth mode in mid-2022, it announced it had secured $180 million to bankroll an audacious mission: to add 10 years to ...
As a postdoctoral researcher at Stanford University, Kristen Fortney used bioinformatics to study the genetics of supercentenarians — people who live to the age of 110 and beyond. Now ...
We sat down with some of the most curious minds in life sciences and healthcare and invited them to share their thoughts on their careers, the future of health ...
